![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Approves Fiasp for Treatment of Children With Diabetes
FDA Approves Fiasp for Treatment of Children With Diabetes
![Purple_Approved_Stamp.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/Purple_Approved_Stamp.gif?t=1576639773&width=430)
January 10, 2020
The FDA approved Novo Nordisk’s Fiasp (insulin aspart injection) 100 u/mL for use as a mealtime insulin option for children with diabetes.
The approval was based on data from a phase 3 trial of the drug’s efficacy and safety compared with conventional insulin aspart in 777 children with type 1 diabetes.
The drug is now available for use in children and adults as either multiple daily injections, continuous subcutaneous insulin infusion pumps, and infusion under supervision by a healthcare professional.
Upcoming Events
-
21Oct